Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein–coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 6 respectively. Report covers products from therapy areas Metabolic Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Genetic Disorders, Infectious Disease, Cardiovascular, Central Nervous System, Musculoskeletal Disorders, Oncology and Respiratory which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Porphyria (Erythropoietic Protoporphyri), Uveitis, Vitiligo, Acne Vulgaris, Acute Ischemic Stroke, Choroidal Neovascularization, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, IgA Nephropathy (Berger's Disease), Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Multiple Sclerosis, Nephrotic Syndrome, Peritonitis, Porphyria Variegata, Psoriatic Arthritis, Pulmonary Fibrosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Ulcerative Colitis and Unspecified Dermatological Disorders.

The latest report Melanocyte Stimulating Hormone Receptor – Drugs In Development, 2022, outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

– The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects

– The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Reasons to Buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Overview

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Companies Involved in Therapeutics Development

Clinuvel Pharmaceuticals Ltd

Mallinckrodt Plc

Mitsubishi Tanabe Pharma Corp

Palatin Technologies Inc

SynAct Pharma AB

Viewpoint Molecular Targeting LLC

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Drug Profiles

afamelanotide acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

AP-1189 – Drug Profile

Product Description

Mechanism Of Action

History of Events

corticotropin – Drug Profile

Product Description

Mechanism Of Action

History of Events

CUV-9900 – Drug Profile

Product Description

Mechanism Of Action

History of Events

dersimelagon phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Next Generation of Compounds – Drug Profile

Product Description

Mechanism Of Action

Parvysmelanotide – Drug Profile

Product Description

Mechanism Of Action

History of Events

PL-8177 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PL-8331 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PL-9643 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PL-9654 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VMT-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Dormant Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Discontinued Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) – Product Development Milestones

Featured News & Press Releases

Jun 29, 2022: SynAct Pharma recieves pre-IND response from the US FDA

Jun 22, 2022: SynAct Pharma submits CTA for clinical phase 2b study in RA

May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference

May 10, 2022: Clinuvel progresses vitiligo study

May 09, 2022: CLINUVEL progresses vitiligo treatment program

May 04, 2022: CLINUVEL Pharmaceuticals : Positive final results in stroke

May 04, 2022: SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet

May 02, 2022: Palatin to present on PL9643 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

May 02, 2022: Palatin to present on PL-9654 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

May 02, 2022: Palatin to present on PL8177 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

Apr 21, 2022: Palatin to present at Eyecelerator American Society of Cataract and Refractive Surgery (ASCRS) 2022

Mar 15, 2022: Afamelanotide in stroke (AIS) – Positive preliminary results

Mar 03, 2022: Palatin hosting key opinion leader webinar on dry eye disease

Feb 14, 2022: CLINUVEL expands DNA repair program with 2nd DNA repair study

Jan 22, 2022: SCENESSE continued in Germany

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Clinuvel Pharmaceuticals Ltd, 2022

Pipeline by Mallinckrodt Plc, 2022

Pipeline by Mitsubishi Tanabe Pharma Corp, 2022

Pipeline by Palatin Technologies Inc, 2022

Pipeline by SynAct Pharma AB, 2022

Pipeline by Viewpoint Molecular Targeting LLC, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.